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Abstract 1 
Rationale:  The incidence of pulmonary arterial hypertension (PAH) is greater in 2 
women suggesting estrogens may play a role in the disease pathogenesis.  3 
Experimentally, in males, exogenously administered estrogen can protect against 4 
PH.  However, in models that display female susceptibility, estrogens may play a 5 
causative role. 6 
Objectives: To clarify the influence of endogenous estrogen and gender in PH and 7 
assess the therapeutic potential of a clinically available aromatase inhibitor. 8 
Methods: We interrogated the effect of reduced endogenous estrogen in males and 9 
females using the aromatase inhibitor, anastrozole, in two models of PH; the hypoxic 10 
mouse and Sugen 5416/hypoxic rat.  We also determined the effects of gender on 11 
pulmonary expression of aromatase in these models and in lungs from PAH patients.   12 
Results: Anastrozole attenuated PH in both models studied, but only in females. To 13 
verify this effect was due to reduced estrogenic activity we confirmed that in hypoxic 14 
mice inhibition of estrogen receptor alpha also has a therapeutic effect specifically in 15 
females.  Female rodent lung displays increased aromatase and decreased BMPR2 16 
and Id1 expression compared to male.  Anastrozole treatment reversed the impaired 17 
BMPR2 pathway in females.  Increased aromatase expression was also detected in 18 
female human pulmonary artery smooth muscle cells compared to male.   19 
Conclusions: The unique phenotype of female pulmonary arteries facilitates the 20 
therapeutic effects of anastrozole in experimental PH confirming a role for 21 
endogenous estrogen in the disease pathogenesis in females and suggests 22 
aromatase inhibitors may have therapeutic potential.  23 
Word count: 238  Keywords: pulmonary hypertension, estrogen, gender.  24 
  25 
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Introduction 1 
 2 
Pulmonary arterial hypertension (PAH) is characterised by severe pulmonary arterial 3 
remodelling and occlusive pulmonary vascular lesions, leading to right ventricular 4 
failure.  Epidemiological studies report a greater incidence of the disease in females; 5 
depending on the disease classification the female to male ratio can be as great as 6 
4:1 (1, 2).  The female predisposition to PAH has given rise to the hypothesis that 7 
female sex hormones, primarily estrogens, may play a causative role in the 8 
development of the condition (3).  However, the role of estrogen in PAH remains 9 
controversial.   10 
The majority of preclinical studies into the role of estrogens in PH have utilised male 11 
animals (4-6) and describe protective effects of estrogen when administered 12 
exogenously.  However, there is compelling evidence that endogenous estrogen 13 
may contribute to the pathogenesis of PH.  Recently, we have described novel 14 
murine models where only female animals develop PH such as mice over-15 
expressing the serotonin transporter gene (SERT+ mouse) (7) and Mts1(8).  In these 16 
models the predominant circulating estrogen 17β-estradiol plays an essential role in 17 
the development of the PH phenotype (7-9).  Estrogen can also induce proliferation 18 
of human pulmonary artery smooth muscle cell (hPASMCs) and may therefore 19 
contribute to the pulmonary artery remodelling observed in PAH (7, 10).   20 
One explanation of the current controversies is that there are gender differences in 21 
the influence of endogenous estrogens on the pathophysiology of PH.  Determining 22 
any gender differences in pulmonary responses to estrogen is vitally important for 23 
understanding the nature and origins of PAH.  To our knowledge, there have been 24 
no comprehensive male versus female comparative studies into the role of 25 
endogenous estrogen in the pulmonary circulation.   26 
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Aromatase (CYP19A1), a member of the cytochrome P450 superfamily, synthesizes 1 
estrogens through the aromatization of androgens.  In pre-menopausal women 2 
estrogen synthesis occurs mainly in the ovarian follicles and corpus luteum, but also 3 
to a lesser extent in non-glandular tissues such as adipose tissue and liver. In 4 
postmenopausal women and men, adipose tissue is a major source of estrogen (11).  5 
Little is known of the role aromatase plays within the pulmonary circulation.  6 
Therefore, to characterise the role of endogenous estrogen in PAH, the effects of an 7 
aromatase inhibitor were studied in two models of PH in male and female animals.  8 
We also assessed aromatase expression in the lung tissue of these animal models 9 
and in lung samples from PAH patients.   10 
 11 
 12 
Methods 13 
An expanded methods section is available in the Online Supplement 14 
Hypoxic Studies 15 
The ability of anastrozole to reduce progression of, and reverse, established PH in 16 
hypoxic mice was assessed.  Hypoxic PH in C57BL/6 mice was achieved with 14 17 
days hypoxia as described previously (10, 12).  Mice were then maintained in 18 
hypoxic conditions for a further 14 days during which time the aromatase inhibitor, 19 
anastrozole was administered (Tocris) 0.3 mgkg-1 or 3 mgkg-1 or vehicle (1% 20 
carboxymethylcellulose) daily (s.c.).  Another cohort of mice were administered with 21 
an ER± antagonist, MPP 2 mgkg-1day-1 for 14days (s.c.).  Age-matched mice housed 22 
in normoxic conditions were studied as controls. See online supplement for ethical 23 
considerations and housing details.   24 
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Sugen 5416 + hypoxia (Su/Hx) Study 1 
The ability of anastrozole to reduce progression of, and reverse, established PH was 2 
also assessed in the rat model of hypoxia + Sugen5416 (Su) as described in detail in 3 
online supplement.  Briefly, Wistar Kyoto rats were given a single injection of Su 4 
20mgkg-1 (s.c.) or 0.9% (s.c.) saline and exposed to hypoxia for 14 days then 5 
retained in normoxia for two weeks during which time they were dosed with 6 
anastrozole (0.03, 0.3 or 3 mgkg-1day-1) or vehicle (1% carboxymethylcellulose) 7 
orally. 8 
 9 
Hemodynamic Measurements 10 
Heart rate, right ventricular systolic pressure (RVSP), systemic arterial pressure and 11 
cardiac output were measured and analyzed as previously described (10, 12, 13).  12 
See online supplement for details. 13 
 14 
Right Ventricular Hypertrophy 15 
Right ventricular hypertrophy (RVH) was assessed by weighing the right ventricular 16 
free wall and left ventricle plus septum. The ratio expressed as RV/LV+S.  See 17 
online supplement for details.  18 
 19 
Lung Histopathology 20 
3µm lung sagittal sections were stained with ±-smooth-muscle actin (<80 µm 21 
external diameter) and microscopically assessed for degree of muscularisation in a 22 
blinded fashion, as previously described (14) and in online supplement.   23 
 24 
  25 
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qRT-PCR 1 
mRNA expression was assessed in lungs of mice by qRT-PCR as described 2 
previously and in online supplement (10).  3 
 4 
Immunoblotting  5 
Protein expression was assessed by immunoblotting in lung and hPASMCs as 6 
described previously and in online supplement (10).  7 
 8 
Lung Immunolocalization  9 
Aromatase expression was investigated in murine, rat and human lung by 10 
immunohistochemistry as described previously and in online supplement (10).  11 
 12 
Measurement of Estradiol Concentrations. 13 
Circulating estradiol was quantified in plasma by ELISA (Estradiol ELISA, Life 14 
Technologies).   15 
 16 
hPASMCs and PAH-PASMCs 17 
hPASMCs were prepared and cultured as described previously and in online 18 
supplement (10).   19 
 20 
Statistics 21 
All data are expressed as mean ± SEM.  Data were analysed using one-way ANOVA 22 
with Dunnett’s or Bonferroni post-hoc analyses and Student’s unpaired t-test (as 23 
appropriate and indicated in figure legends) using GraphPad Prism 5 software.   A P 24 
value < 0.05 was considered statistically significant.  25 
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Results 1 
 2 
Inhibition of aromatase attenuates experimental PH in female but not male mice.  3 
In female mice anastrozole reduced hypoxia-induced increases in RVSP, RVH and 4 
pulmonary vascular remodelling (PVR) (Figure 1A-D).  However, in male mice, 5 
anastrozole when used at the most effective dose (3mgkg-1day-1) had no significant 6 
effect on hypoxia-induced elevations in RVSP, RVH or PVR (Figure 1E-H).  7 
Anastrozole had no significant effect on mean systemic arterial blood pressure or 8 
heart rate (Figure E1 online supplement).  9 
To confirm that this effect was not due to any off-target effects of anastrozole, the 10 
effect of MPP, an ER± antagonist was assessed.  MPP was selected as ER± protein 11 
levels were found to be significantly elevated in pulmonary arteries from female 12 
hypoxic mice, whilst ER²  was significantly reduced.  No significant differences in the 13 
expression of ER± or ER²  were observed in pulmonary arteries from male mice 14 
(Figure E2 online supplement).  MPP markedly attenuated hypoxia-induced 15 
increases in RVSP and PVR in females but had no therapeutic effect in males 16 
(Figure E3 online supplement). 17 
In female Su/Hx rats anastrozole reduced increases in RVSP, RVH, PVR and 18 
reversed the development of occlusive vascular lesions (Figure 2A-E).  In contrast to 19 
females, anastrozole had no significant effect on Su/Hx-induced changes in RVSP, 20 
RVH or PVR in male animals (Figure 3A-E). 21 
Cardiac and pulmonary function were assessed by echocardiography.  In female rats 22 
anastrozole had no effect on cardiac output, but did slightly restore decreased 23 
pulmonary artery acceleration time (PAAT) (Figure E4 online supplement).  In Su/Hx 24 
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male rats anastrozole had no effect on cardiac output or PAAT (Figure E4 online 1 
supplement).  2 
 3 
Aromatase expression in hypoxic and Su/Hx-induced PH. 4 
Weak aromatase expression was observed in pulmonary arteries from normoxic 5 
mice whilst expression was abundant in hypoxic mice, localising to the smooth 6 
muscle layer (Figure 4A).  Analysis of whole lung tissue by immunoblotting showed 7 
that female mice express significantly higher levels of aromatase protein in whole 8 
lung compared to male in both normoxic and hypoxic conditions (Figure 4B).  9 
Similarly, in pulmonary arteries from normoxic rats negligible to weak aromatase 10 
staining was observed whilst expression was abundant in arteries from Su/Hx rats, 11 
localising within the vascular smooth muscle (Figure 5A).  Aromatase staining was 12 
absent from the endothelial layer of rat pulmonary arteries (Figure 5B).  In addition, 13 
aromatase was absent from endothelial cells within the small occlusive vascular 14 
lesions observed in Su/Hx rat lung (Figure 5C).  Male rats also express significantly 15 
lower aromatase protein levels in the whole lung compared to female under both 16 
normoxic and Su/Hx conditions (Figure 5D).  Exposure to Su/Hx had no effect on 17 
aromatase expression in female or male rat lung when compared to normoxic control 18 
(Figure 5D).   19 
 20 
Aromatase expression in human lung. 21 
Aromatase was found to be expressed in pulmonary arteries of control, female PAH 22 
and male PAH patients localising mainly within the smooth muscle layer (Figure 6A).  23 
Aromatase immunostaining was also present in vascular lesions from PAH patients 24 
(Figure 6B) also localising to the smooth muscle layer.  Aromatase immunoreactivity 25 
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was absent in the endothelium of most PAH patients regardless of BMPR2 status 1 
(Figure 6B and E5B).  In addition, there was no evidence of aromatase expression in 2 
human microvascular pulmonary artery endothelial cells (hMPAECs) (Figure E5C 3 
online supplement).  PASMCs isolated from control postmenopausal females 4 
express significantly higher levels of aromatase than those from males (Figure 6C), 5 
however, no significant difference in aromatase expression in PASMCs from female 6 
control versus female PAH patients was observed (Figure 6D).   7 
 8 
Effect of anastrozole on circulating estrogen levels. 9 
Anastrozole 0.3mgkg-1 and 3mgkg-1 decreased levels of circulating estradiol, the 10 
major bioactive estrogen in female mice and had no effect on circulating estrogen 11 
levels in the male mice. Furthermore, hypoxia alone had no effect of circulating 12 
estrogen levels in either female or male mice (Figure 7A)  13 
In the Su/Hx rat model, estradiol levels were undetectable in male rats.  However, in 14 
female rats, circulating estradiol levels were found to be significantly elevated in the 15 
Su/Hx rats compared to normoxic controls (Figure 7B).  Anastrozole reduced 16 
circulating estradiol levels in a dose-dependent fashion.  Analysis across the female 17 
Su/Hx treatment groups revealed a significant correlation between circulating 18 
estradiol concentrations and RVH (Figure 7C) as well as the percentage of 19 
muscularised pulmonary arteries (Figure 7D). 20 
 21 
Effects of anastrozole on hypoxia and Su/Hx-mediated changes in bone 22 
morphogenetic protein receptor 2 (BMPR2). 23 
In normoxic conditions lung transcript levels of BMPR2 were significantly lower in 24 
female mice than male.  Administration of anastrozole resulted in a significant 25 
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upregulation of BMPR2 in female lung, restoring levels to that of males whilst having 1 
no effect on BMPR2 levels in male lung (Figure 8A).  In hypoxia, BMPR2 transcript 2 
and protein levels were significantly reduced in both male and female lung.  3 
Anastrozole treatment restored the hypoxia-mediated downregulation in BMPR2 in 4 
females (Figure 8A-B) but not males (Figure 8A&C).  In the Su/Hx rat model, BMPR2 5 
transcript was also found to be significantly decreased in both male and female lung 6 
compared to normoxic controls (Figure 8D-F).  This effect was reversed in female 7 
rats treated with anastrozole 3mgkg-1day-1 (Figure 8D-E) but not male rats (Figure 8 
8F).  The male rats had significantly higher normoxic transcript levels of BMPR2 9 
compared to females, consistent with our observations in mice (Figure 8D).   10 
Female normoxic mouse and rat lung demonstrated significantly lower levels of Id1 11 
and Id3 (Figure E6 online supplement) than males.  In females anastrozole 12 
significantly elevated Id1 and Id3 to levels similar to that observed in males but had 13 
no effect on Id1 and Id3 expression in male lung.  Id1 expression was significantly 14 
reduced in both male and female disease models, whilst Id3 was specifically 15 
downregulated in males.  The PH-mediated decreases in Id1 were rescued by 16 
administration of anastrozole in female animals but not male (Figure E6 online 17 
supplement).  ER± antagonist MPP also restored hypoxia-mediated reductions in 18 
BMPR2 and Id1 (Figure E7 online supplement). 19 
 20 
 21 
Discussion 22 
 23 
Increased synthesis of estrogen has been clinically associated with porto-pulmonary 24 
hypertension (15) and estrogen is causative in female susceptible models of PH (7-25 
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9).  Studies into the role of estrogen in PAH have failed to reach a concensus, mainly 1 
due to the variety of experimental approaches adopted.  Indeed, many experimental 2 
studies have demonstrated a protective effect of estrogen in male animals (4-6).  3 
These valuable studies examined the influence of estrogen administered to males 4 
where estrogen levels are normally extremely low or undetectable.  In addition, these 5 
studies utilise intact males, hence the presence of high endogenous testosterone 6 
combined with high circulating estrogen levels (due to the exogenously added 7 
estradiol) are not a state that would normally occur physiologically and may influence 8 
interpretation of results.  In the instance of monocrotaline (MCT)-induced PH the 9 
beneficial effects of estrogen may be owing to the fact that MCT is a toxin reported to 10 
cause gonadal toxicity and reduce estrogen levels (16). In our experimental design 11 
we wished to compare males and females and address a different question: ‘what is 12 
the role of endogenous estrogen and is it different in intact males and females’? 13 
The data presented in this study explains some of these current controversies by 14 
providing several unique insights into the influence of gender and endogenous 15 
estrogen in the development of PH.  We demonstrate that endogenous estrogen 16 
contributes to the pathophysiology of PH in females and that there is potential for 17 
local estrogen synthesis in PASMCs.  Given the previously demonstrated mitogenic 18 
effects of estrogen in PASMCs (7), we also describe a unique pro-proliferative 19 
phenotype in female PASMCs owing to elevated aromatase and reduced BMPR2 20 
and Id1 expression. 21 
Using anastrozole we inhibited the enzyme aromatase, which is responsible for 22 
estrogen synthesis, to determine the role of endogenous estrogen on established PH 23 
in females and males.  Anastrozole reduced plasma estrogen and attenuated 24 
hypoxia and Su/Hx-induced changes in RVSP, RVH and PVR in females. 25 
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Furthermore, in the female Su/Hx model a positive correlation between circulating 1 
estrogen concentrations and disease severity was established, suggesting the 2 
therapeutic effects of anastrozole were related to a decrease in plasma estrogen 3 
levels.  In the males, there was no therapeutic effect of anastrozole; plasma estrogen 4 
was below the level of detection and unaffected by anastrozole.   5 
We also demonstrated that there is a dysregulation in the expression of estrogen 6 
receptors in hypoxic female mice but not male, with ER± expression significantly 7 
increased and ER²  decreased in female pulmonary artery whilst both receptors 8 
remain unaffected in males.  Furthermore, we show that an ER± antagonist, MPP, 9 
has selective therapeutic effect in female hypoxic mice, not male.  This corroborates 10 
our hypothesis that endogenous estrogen is pathogenic in female models of PH.  11 
Anastrozole is a third generation highly selective competitive inhibitor of aromatase 12 
and as such has few off-target actions.  Preclinical studies show that even when 13 
used up to doses of 10mgkg-1 in rats no reported disturbances in adrenal 14 
steroidogenesis were observed (17).   15 
Estrogen is widely described to be cardioprotective due to its direct action on the 16 
heart.  Epidemiological evidence shows that pre-menopausal women have a lower 17 
risk for mortality from cardiovascular diseases than men (18-20).  Given the 18 
cardioprotective effects of estrogen there is concern that treatment with aromatase 19 
inhibitors may facilitate right ventricular dysfunction.  Hence we interrogated the 20 
influence of anastrozole on heart function in the Su/Hx rat model by 21 
echocardiography.  Anastrozole had no detrimental effects on cardiac output or 22 
pulmonary artery acceleration time in rats.  These findings suggest that depletion of 23 
estrogen is not having detrimental effects on the heart that might limit the use of 24 
anastrozole in the treatment of PAH.  Aromatase inhibitors are currently widely 25 
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prescribed to patients with estrogen receptor-sensitive breast cancer and many 1 
systemic side-effects have been investigated  Available data do not support an 2 
association between aromatase inhibitors and an increased risk of cardiovascular 3 
disease, PAH or a deleterious effect on lipid metabolism in humans (21).   4 
Aromatase was expressed in small pulmonary arteries of both female and male 5 
rodents localising within the smooth muscle layer. However, aromatase expression 6 
was significantly higher in the lungs from female rats and mice than males.  This may 7 
partially explain the increased therapeutic effect of anastrozole in the females.  We 8 
also verified that aromatase is expressed in the smooth muscle of pulmonary arteries 9 
in human lung, demonstrating that aromatase is abundantly expressed in vascular 10 
smooth muscle from control non-PAH lung sections and in complex vascular lesions.  11 
This coupled with the elevated aromatase expression observed in female PASMCs 12 
suggests female PASMCs have the ability to synthesis higher levels of estradiol that 13 
male.  This may contribute to the female susceptibility to PAH given the mitogenic 14 
properties of estradiol.   15 
This is the first study to report that there is the potential for local estrogen production 16 
in pulmonary arteries.  We could find no evidence for aromatase expression in the 17 
endothelium of rats, mice or human in our studies regardless of their disease status.  18 
Likewise, hMPAECs do not express aromatase.  This suggests that estrogen 19 
produced by PASMCs that exerts a paracrine proliferative effect on adjacent 20 
PASMCs.  Indeed, we have previously demonstrated that estrogen induces 21 
proliferation in human PASMCs (7, 8).  Estrogen synthesized within extragonadal 22 
compartments has been postulated to act at a local tissue level in a paracrine 23 
fashion (22).  Thus, the total amount of estrogen synthesized by these extragonadal 24 
sites may be small but the local tissue concentrations achieved high enough to exert 25 
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significant biologic influence locally (11).  Given the expression of aromatase in the 1 
smooth muscle layer of the pulmonary artery the local concentration of estrogen in 2 
the pulmonary artery may be much greater than circulating concentrations.  Estrogen 3 
levels will also be affected by metabolism.  We have previously shown that 4 
expression of cytochrome P450 1B1 (CYP1B1) an estrogen metabolising enzyme is 5 
dysregulated in the Su/Hx mouse model of PH (10).  Differences in estrogen 6 
metabolism between the hypoxic mouse model and Su/Hx rat model of PH may 7 
explain why circulating estrogen levels are elevated in Su/Hx rats but not hypoxic 8 
mice.   9 
Loss of function associated with BMPR2 mutations in PAH results in reduction of the 10 
growth inhibitory effects of BMPs, facilitating the proliferation of PASMCs and 11 
contributing to pulmonary vascular remodelling (23).  BMPR2 is also often observed 12 
to be down-regulated in animal models of PAH (24, 25).  Here we showed that 13 
expression of BMPR2 and its downstream mediator Id1 are significantly decreased 14 
in the lungs of normoxic female rodents compared with males.  The significantly 15 
lower levels of BMPR2 and Id1 in females can be restored to levels similar to that 16 
observed in males by anastrozole, suggesting estrogen may be responsible for the 17 
suppressed BMPR2 signaling axis in females.  Furthermore, anastrozole treatment 18 
restored hypoxic and Su/Hx-mediated reductions in BMPR2 mRNA and protein 19 
levels in female rodents whilst having no effect on males. These observations 20 
provide one further explanation for the selective therapeutic effect of anastrozole on 21 
the development of PH in female models, i.e. endogenous estrogen in the lungs of 22 
females is greater due to increased aromatase expression; this combined with the 23 
effects of hypoxia or Su/Hx, decreases expression of BMPR2 which is already 24 
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significantly reduced in females.  Consequently anastrozole, by decreasing 1 
endogenous estrogen levels, has a selective therapeutic effect in females.  2 
In hPAH families, penetrance of PAH in BMPR2 mutation carriers is low, suggesting 3 
other risk factors must influence the emergence of the PAH phenotype.  Indeed, 4 
further predisposing genes such as KCNK3 and TOPBP4 have been recently 5 
identified (26, 27).  Whilst increased aromatase expression combined with 6 
decreased BMPR2 signaling may predispose susceptible females to PAH it is 7 
unlikely that these factors alone are responsible for the clinical presentation of 8 
disease in all females; and clearly males develop PAH, displaying poorer survival 9 
rates than females (1).  Our results suggest that once the disease is established, the 10 
increased influence of both circulating and locally produced estrogen in women, 11 
results in an enhanced pathogenic effect on the pulmonary circulation compared to 12 
males.  Consistent with this, female PAH patients have 2.8-fold higher number of 13 
plexiform lesions compared with their male counterparts (20).  14 
However, in some patient sub-groups including PAH associated with HIV, sleep 15 
apnea and portopulmonary hypertension the prevalence of PAH is greater in males 16 
(1).  However, these primary conditions occur more frequently in men, potentially 17 
influencing the male:female ratio of those developing PAH (e.g.(28-30)).  In addition, 18 
estrogen may contribute to the disease pathophysiology in males within these 19 
subgroups.  For instance, in HIV dysregulation in sex hormone concentrations have 20 
been reported in both sexes.  In one study estradiol was reported to significantly 21 
increase over an 18 month period in male HIV patients (31).  Furthermore, 22 
obstructive sleep apnea is most common in obese men (29), in which elevated 23 
circulating estrogen levels are common due to the high expression and activity of 24 
aromatase within adipose tissue (32, 33).  Polymorphisms in the aromatase gene 25 
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have also been associated with increased risk of portopulmonary hypertension in 1 
patients with liver disease.  These polymorphisms are associated with increased 2 
estradiol production, supporting a functional effect of aromatase activity in both male 3 
and female patients (15).  Thus, elevated estrogen is observed in the males in these 4 
PAH subgroups.  This is not incompatible with the suggestion that when elevated, 5 
endogenous estrogen may contribute to the pathobiology PAH in males as well as 6 
females.  7 
The results of this study also suggests that non-estrogenic contraceptives be 8 
recommended to pre-menopausal PAH patients, although these are already contra-9 
indicated for PAH patients due to the increased risk of venous thromboembolic 10 
disease (34).   11 
In summary, we have demonstrated that endogenous estrogen plays a causative 12 
role in the development of experimental PH in female animal models of the disease. 13 
Inhibition of aromatase with anastrozole reduces moderate and severe experimental 14 
PH in female animals via reduction in endogenous estrogen.  The reason for the 15 
sexual dimorphism in the therapeutic effects of anastrozole may be due to a unique 16 
phenotype of female pulmonary arteries.  We propose that increased capability of 17 
female PASMCs to produce estrogen locally via aromatase contributes to a 18 
reduction in the BMPR2 signalling axis and may contribute to the pathology and 19 
increased incidence of the disease in females.  The results partly explain the 20 
‘estrogen paradox’ and suggest that aromatase inhibitors may have therapeutic 21 
potential in the treatment of PAH in females. 22 
 23 
 24 
  25 
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Figure 1 1 
Inhibition of aromatase attenuates chronic hypoxia-induced PH in female mice.  2 
Female mice:  Effects of the aromatase inhibitor, anastrozole (ANA) 0.3 mgkg-1day-1 3 
and 3 mgkg-1day-1 for 14 days on (A) RVSP (n=8-10 per group), (B) RVH (n=8-10 4 
per group) (as determined by RV/LV+S ratio) and (C) the % of remodelled pulmonary 5 
arteries in normoxic mice and hypoxic female mice with established PH (n=6 per 6 
group).  (D) Representative images of pulmonary arteries from normoxic and hypoxic 7 
female mice treated with or without anastrozole 3 mgkg-1day-1 (brown staining 8 
indicates ±-smooth muscle actin; scale bar (-) indicates 20µm).  Male mice:  Effects 9 
of ANA 3 mgkg-1day-1 for 14 days on (E) RVSP (n=8-10 per group), (F) RVH (n=8-10 10 
per group) (as determined by RV/LV+S ratio) and (G) the % of remodelled 11 
pulmonary arteries in normoxic mice and hypoxic male mice with established PH 12 
(n=6 per group).  (H) Representative images of pulmonary arteries from normoxic 13 
and hypoxic male mice treated with or without anastrozole 3 mgkg-1day-1 (brown 14 
staining indicates ±-smooth muscle actin; scale bar (-) indicates 20µm).    Data 15 
displayed as mean ± SEM. **p<0.01 and ***p<0.001 as indicated, determined by 16 
one-way ANOVA with Bonferroni post test. RVSP = right ventricular systolic 17 
pressure, RVH = right ventricular hypertrophy and RV/LV+S = right ventricle/left 18 
ventricle + septum. 19 
  20 
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Figure 2 1 
Inhibition of aromatase attenuates Su5416/hypoxia (Su/Hx)-induced PH in female 2 
rats.  (A) RVSP (n=5-8 per group), (B) RVH (n=5-8 per group) (as determined by 3 
RV/LV+S) and (C) the % remodelled pulmonary arteries (n=5-8 per group) were 4 
assessed on day 14 (D14) and day 28 (D28) following administration of Su/Hx in 5 
female rats treated with or without anastrozole (ANA) 0.03 mgkg-1day-1, 0.3 mgkg-6 
1day-1 or 3 mgkg-1day-1 for 14 days in female rats (from D14-28).  Representative 7 
images showing (D) ±-smooth muscle actin (±-SMA) staining in pulmonary arteries 8 
from Su/Hx female rats treated with or without anastrozole (±-SMA = brown staining; 9 
scale bar (-) indicates 20µm). (E) The percentage of pulmonary arteries which are 10 
fully occluded in female rats treated with or without anastrozole (n=5-8) and (F) 11 
representative image of an occluded pulmonary artery (±-SMA = pink, vWF = black; 12 
scale bar (-) indicates 20µm). Data displayed as mean ± SEM.  * p<0.05, **p<0.01 13 
and ***p<0.001 as indicated, # p<0.01 versus D14 Su/Hx as determined by one-way 14 
ANOVA with Dunnett’s post test. RVSP = right ventricular systolic pressure and RVH 15 
= right ventricular hypertrophy. 16 
  17 
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Figure 3 1 
Inhibition of aromatase does not attenuate Su5416/hypoxia (Su/Hx)-induced PH in 2 
male rats.  (A) RVSP (n=5-8 per group), (B) RVH (n=5-8 per group) and (C) the % 3 
remodelled pulmonary arteries (n=5-8 per group) were assessed on day 14 (D14) 4 
and day 28 (D28) following administration of Su/Hx in male rats treated with or 5 
without anastrozole (ANA) 3 mgkg-1 (from D14-28)  Representative images showing 6 
(D) ±-SMA staining in pulmonary arteries from SU/Hx male rats treated with or 7 
without anastrozole (±-SMA = brown; scale bar (-) indicates 20µm). (E) The 8 
percentage of pulmonary arteries which are fully occluded (n=5-8 per group) in male 9 
rats treated with or without anastrozole 3mgkg-1 and (F) representative image of an 10 
occluded pulmonary artery (±-SMA = pink, vWF = black ; scale bar (-) indicates 11 
10µm). Data displayed as mean ± SEM. * p<0.05, **p<0.01 and ***p<0.001 as 12 
indicated, determined by one-way ANOVA with Dunnett’s post test. RVSP = right 13 
ventricular systolic pressure and RVH = right ventricular hypertrophy . 14 
  15 
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Figure 4 1 
Effect of chronic hypoxia on aromatase expression in mouse pulmonary artery and 2 
whole lung. Representative images showing (A) aromatase immunolocalisation in 3 
pulmonary arteries (scale bar (-) indicates 20µm) with 3µm consecutive sections 4 
showing ±-smooth muscle actin (±-SMA) and von Willebrand factor (vWF) 5 
(representative of n=4 per group, brown staining).  For IgG control see online 6 
supplement Figure E5.  (B) Representative immunoblot and quantification of 7 
aromatase protein expression in whole lung from normoxic and hypoxic, female and 8 
male mice (n=5-6 per group). Data displayed as mean ± SEM. *p<0.05 and ** p<0.01 9 
as indicated, determined by one-way ANOVA with Bonferroni post test. 10 
  11 
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Figure 5 1 
Effect of Su5416/hypoxia (Su/Hx) on aromatase expression in rat pulmonary artery 2 
and whole lung. Representative images showing (A) aromatase immunolocalisation 3 
in pulmonary arteries (scale bar (-) indicates 20µm) with 3µm consecutive sections 4 
showing ±-smooth muscle actin (±-SMA) and von Willebrand factor (vWF) 5 
(representative of n=4 per group, brown staining) (for IgG control refer to  online 6 
supplement Figure E5.  (B)  Representative image showing the absence of 7 
aromatase immunolocalisation in the endothelial layer of rat pulmonary artery (scale 8 
bar (-) indicates 50µm (x400 magnification)) with 3µm consecutive sections showing 9 
±-smooth muscle actin (±-SMA) and von Willebrand factor (vWF) (brown staining).  10 
(C)  Representative image showing aromatase immunolocalisation in small occlusive 11 
vascular lesions from SuHx rat (scale bar (-) indicates 20µm) with 3µm consecutive 12 
sections showing ±-smooth muscle actin (±-SMA) and von Willebrand factor (vWF) 13 
(brown staining).  (D) Representative immunoblot and quantification of aromatase 14 
protein expression in whole lung from normoxic and hypoxic, female and male rats 15 
(n=5-6 per group). Data displayed as mean ± SEM. *p<0.05 and ** p<0.01 as 16 
indicated, determined by one-way ANOVA with Bonferroni post test.  17 
  18 
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Figure 6   1 
Aromatase expression in human PAH.  (A) Representative images showing 2 
aromatase immunolocalisation in control and female and male PAH patients.  (B) 3 
Representative images showing examples of aromatase immunolocalisation in 4 
vascular lesions from PAH patients (aromatase (AROM) = pink; ±-smooth muscle 5 
actin (±-SMA) and von Williebrand factor (vWF) = brown; scale bar (-) indicates 6 
100µm; for IgG control see online supplement Figure E5).  Aromatase protein 7 
expression was also assessed by immunoblotting using human pulmonary artery 8 
smooth muscle cells (hPASMCs). (C) Representative immunoblots and graph 9 
showing quantification comparing aromatase expression in hPASMCs isolated from 10 
male and female control (n=4 samples per group) and (D) female control and female 11 
PAH patients (n=4 samples per group). Data displayed as mean ± SEM. ***p<0.001 12 
as indicated, determined by two-tailed, unpaired t-test.  1-11, a,e,i and j correspond 13 
to patient information on human tissues and cells referred to in online supplement 14 
Table E3. 15 
  16 
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Figure 7 1 
Effect of aromatase inhibition on circulating estradiol (E2) levels in models of 2 
pulmonary hypertension.  (A) Circulating plasma E2 levels in normoxic and hypoxic 3 
female and male mice treated with or without anastrozole (ANA) for 14 days (n=5 per 4 
group). Data displayed as mean ± SEM.  *p<0.05, **p<0.01 and ** p<0.001 as 5 
indicated, determined by one-way ANOVA with Bonferroni post test. (B)  Circulating 6 
E2 levels in female Su/Hx rats treated with or without 0.3 mg-1kg-1day-1, 1 mg-1kg-7 
1day-1 or 3 mg-1kg-1day-1 anastrozole (n=4-5 per group). Data displayed as mean ± 8 
SEM.  *p<0.05 and *** p<0.001 as indicated, determined by one-way ANOVA with 9 
Dunnett’s post test.  Plasma E2 levels from female Su/Hx rats were used to 10 
determine if there was any correlation with disease severity using Pearson’s 11 
coefficient.  Significant correlation between plasma E2 levels and (C) RVH (as 12 
determined by RV/LV+S) (n=30) and (D) the percentage of muscularised pulmonary 13 
arteries (n=30). *p<0.05 and **p<0.01 as indicated.  All E2 concentrations are 14 
expressed as a percentage relative to normoxic set at 100%.   15 
  16 
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Figure 8   1 
Effects of aromatase inhibition on hypoxia and Su/Hx-induced changes in BMPR2 2 
expression.  A-C: hypoxic mice.  (A) Relative gene expression levels of BMPR2 in 3 
male and female normoxic and hypoxic mouse lung treated with or without 4 
anastrozole 3 mgkg-1day-1 (n=6 per group).  Representative immunoblot and 5 
quantification showing effects of anastrozole 3 mgkg-1day-1 on BMPR2 protein 6 
expression in (B) female and (C) male normoxic and hypoxic mouse lung (n=6 per 7 
group).  D-F: Su/Hx rats.  (D) Relative gene expression levels of BMPR2 in female 8 
and male normoxic and Su/Hx rat lung treated with or without anastrozole 3 mgkg-9 
1day-1 for 14 days (n=5-6 per group).  Representative immunoblot and quantification 10 
showing effects of anastrozole 3 mgkg-1day-1 on BMPR2 protein expression in (E) 11 
female and (F) male lung from normoxic and Su/Hx rats treated with or without 12 
anastrozole 3 mgkg-1day-1 for 14 days (n=5-6 per group). Gene expression levels are 13 
normalised to ² -2-microglobulin (² 2M). Data displayed as mean ± SEM. *p<0.05 and 14 
**p<0.01 as indicated, determined by one-way ANOVA with Bonferroni post test.   15 
 16 
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Online Data Supplement 
Gender–dependent Influence of Endogenous Estrogen in Pulmonary 
Hypertension. 
Kirsty M. Mair, Audrey F Wright, Nicholas Duggan, David J. Rowlands, Martin J. 
Hussey, Sonia Roberts, Josephine Fullerton, Margaret Nilsen, Lynn Loughlin, 
Matthew Thomas & Margaret R. MacLean. 
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Supplemental Methods 
 
Ethical Information 
All animal procedures conform to the UK Animal Procedures Act (1986) and the 
Guide for the Care and Use of Laboratory Animals published by the US National 
Institutes of Health (NIH publication No. 85–23, revised 1996).  Experimental 
procedures using human lung tissue and hPASMCs conform to the principles 
outlined in the Declaration of Helsinki and were approved by Cambridgeshire 1 
Research Ethics committee (REC reference: 08/H0304/56).  All non-PAH human 
lung biopsies were confirmed as macroscopically normal and collected from patients 
undergoing pneumonectomy with no reported presence of PAH.  
 
Animals 
Male and female C57BL/6 mice (aged 8-12 weeks) and Wistar Kyoto rats (~200g) 
were purchased from Harlan, UK.  Rodents were housed in a 12-hour light-dark 
cycle with access to food and water ad libitum.  Animals were housed together to 
promote synchronisation of the estrous cycle.  The method we employ to check the 
estrous cycle in cohorts of mice is as follows.  All female mice are housed together 
for two weeks prior to the study. A blunt, shortened tip of a Pasteur pipette is placed 
at the vaginal orifice. One drop of PBS is gently expelled into the vagina and 
aspirated back before being transferred to a microscope slide. Smears are examined 
microscopically and classified as to the stage of the cycle according to criteria 
modified from those of Nelson et al., (1).  Our analysis indicates that even after 4 
days female mice start to synchronise and by two weeks we are convinced that they 
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are fully synchronised. In addition, plasma levels of estrogen are very consistent and 
within a tight range for our female study animals.  
 
In Vivo Effects of MPP Dihydrochloride Administration 
Prior to the induction of hypoxia, C57Bl/6 mice were administered with either ER± 
antagonist, MPP dihydrochloride [chemical name- 1,3-Bis(4-hydroxyphenyl)-4-
methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] (MPP) 2 mgkg-
1day-1 or vehicle.  Under general anaesthesia (1% - 3% (v/v) isoflurane 
supplemented with O2) pellets containing either ER± antagonist, MPP (0.56mg/14 
day pellet, Innovative Research of America, Florida, USA) or vehicle were inserted 
subcutaneously into the dorsal neck of male and ovary intact female mice using a 
sterile 12-gauge hypodermic needle.  The development of PH was then assessed in 
normoxic animals and animals exposed to hypobaric hypoxia (550mbar, equivalent 
to 10% O2) for 14 days in the presence of MPP or vehicle.  n=6-10 mice per 
experimental group.     
 
Sugen 5416+hypoxia 
The underlying concept is that two hits are required to generate severe obliterative 
PH in the rat.  Su5416 binds with high affinity to the intracellular tyrosine kinase 
domain of VEGFR1 (flt1) and VEGFR2 (KDR) and inhibits signal transduction via 
these receptors, inducing lung endothelial cell apoptosis (2).  Su5416-induced 
pulmonary endothelial cell apoptosis in combination with chronic hypoxia results in 
the development of angioproliferation and obliterative pulmonary vascular lesions 
(3).  
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The vascular endothelial growth factor receptor inhibitor Sugen (Su) 5416 was 
suspended in 0.5% (wt/vol) carboxymethylcellulose sodium, 0.9% (wt/vol) NaCl, 
0.4% (vol/vol) polysorbate, and 0.9% (vol/vol) benzyl alcohol in dH2O.  Rats (~200g) 
were administered with a single injection of Su5416 (Sigma UK, 20 mgkg-1 s.c.) or 
0.9% saline and exposed to chronic hypoxia for 14 days.  At this point, a sub-set of 
animals were taken for hemodynamic and histological analysis.  The remaining rats 
were subsequently transferred to normoxic conditions for a further 14 days during 
which time the received the aromatase inhibitor anastrozole 0.03, 0.3 or 3 mgkg-
1day-1 or vehicle (1% carboxymethylcellulose) by oral administration.  Vehicle dosed 
rats housed in normoxic conditions only were studied as controls. 
 
Echocardiographic Assessment and pressure measurements in rats 
In rats, right ventricular systolic pressure was measured by right heart catheterization 
through the right jugular vein (MPVS-300 System; Millar, Houston, TX).  
Echocardiographic assessments were performed by ultrasound on 2% isoflurane-
anesthetized animals.  A Vivid7 (GE Healthcare, Little Chalfont, Buckinghamshire, 
UK) ultrasound system equipped with 13-MHz probe was used. The pediatric probe 
was placed in a parasternal long axis position to visualize the PA outflow tract. 
Pulsed flow Doppler imaging was then overlaid to observe the dynamics of blood 
flow through the PA valve.  Changes in PA acceleration/ejection time ratio (time 
taken from start of flow to maximal velocity or to the end of flow) were determined.  
The cardiac function was further analyzed by cardiac output (CO) values as 
previously described (4).  Analysis was performed using Echo-PAC dimension 
software. 
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Right Ventricular Hypertrophy 
Right ventricular hypertrophy (RVH) in mice was assessed by weight measurement 
of the right ventricular free wall and left ventricle plus septum. The ratio expressed is 
RV/LV+S.   
 
Lung Histopathology 
3µm lung sagittal sections were stained with elastic Van Gieson and pulmonary 
arteries (<80 µm external diameter) microscopically assessed for degree of 
muscularisation in a blinded fashion, as previously described (5).  Remodelled 
arteries were confirmed by the presence of double-elastic laminae.  Briefly, 
percentage remodelling (percent of remodelled vessels) was defined for each animal 
by the number of remodelled vessels divided by the total number (e80 per lung) of 
vessels observed in the lung. To visualize the degree of smooth muscle thickening, 
lungs were stained with ±-smooth muscle actin (Abcam, UK).  Briefly, 3 µm sagittal 
sections were deparaffinised and rehydrated through a xylene-ethanol gradient. After 
epitope retrieval, endogenous peroxidase and biotin activity was blocked and lung 
tissue was incubated for 16 hours with anti-rabbit ±-smooth muscle actin antibody 
(dilution 1:1000 Abcam, UK) or IgG control.  After secondary incubation, ±-smooth 
muscle actin was visualized with the DAB substrate kit (Vector Laboratories, UK), 
which stained brown/dark brown.  The presence and degree of pulmonary vascular 
occlusion formation were assessed in lungs from chronic hypoxic+SU5416–treated 
rats as previously described (5).  Images were captured using a Zeiss Axio Imager 
M1.  
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Quantitative Reverse Transcription–Polymerase Chain Reaction 
mRNA expression was assessed in the lungs of mice by quantitative reverse 
transcription–polymerase chain reaction.  At necropsy, lung tissue from each rodent 
was removed and snap frozen.  RNA was then extracted from the lung tissue or 
pulmonary artery smooth muscle cells and gene expression quantified using 
TaqMan® gene expression assays (assay details shown in Supplemental Table 1).  
ViiA7 Real-time PCR system (Applied Biosystems) was programmed for PCR 
conditions 95oC for 10 minutes followed by 50 cycles of 95oC for 15 seconds and 
60oC for 1 minute.  Results were normalised to ² -2-microglobulin. The fold change 
for every gene was obtained using the 2-” ” Ct method and expressed relative to 
normoxic female mice or rats as appropriate.  
 
Immunoblotting  
Protein expression was assessed in whole lung.  Briefly, lung tissue was 
homogenised in radioimmunoprecipitation assay buffer via ultrasonic 
homogenization.  Samples were denatured and electrophoresed on SDS-PAGE gel. 
30µg protein for each sample was loaded per well.  Separated proteins were 
transferred to PVDF membrane and incubated for 1 hour with 5% milk/TBST (w/v) 
before incubating overnight at 4oC with antibodies against aromatase, TPH-1, 
BMPR2 and GAPDH (for details of primary antibodies used refer to Supplemental 
Table 2).  Aromatase, TPH-1, BMPR2 and GAPDH molecular weights were detected 
at 55, 51, 115 and 37 kDa, respectively.  Densitometric analysis was performed with 
TotalLab TL100 software. Data are expressed relative to GAPDH density.  
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Lung Immunolocalization  
Pulmonary vascular aromatase expression was investigated in murine, rat and 
human lung by immunohistochemistry.  Briefly, 5 µm sagittal sections were 
deparaffinised and rehydrated through a xylene-ethanol gradient. After epitope 
retrieval, endogenous peroxidase and biotin activity was blocked and lung tissue was 
incubated for 16 hours with anti-rabbit aromatase antibody or IgG control.  5µm 
consecutive sections were also incubated with ±-smooth muscle actin (±-SMA) and 
von Willebrands factor (vWF) to determine aromatase localisation within the vessel 
wall.  After secondary incubation, aromatase, ±-SMA and vWF were visualized with 
the DAB substrate kit (Vector Laboratories, UK), which stained brown/dark brown.  In 
the case of human lung tissue aromatase was visualized with the VIP substrate kit 
(Vector Laboratories, UK), which stained pink.  Images were captured using a Zeiss 
Axio Imager M1.  For details of primary antibodies used refer to Supplemental Table 
2. 
 
Human microvascular pulmonary artery endothelial cells (hMPAECs) 
 (hMPAECs) were grown from surgically discarded lung tissues collected from 
donors that underwent pulmonary resection for reasons not related to PH (female, 42 
year old caucausian) (PromoCell).  Cultured PAECs were grown in Endothelial Cell 
Growth Medium 2 (EGM-2; PromoCell) and utilized for experimental analysis from 
passage 3–6 inclusive.  
 
hPASMCs and PAH-PASMCs 
hPASMCs were provided by Professor N.W. Morrell (University of Cambridge, 
Cambridge, UK).  Briefly, hPASMCs were explanted from the distal pulmonary 
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arteries of macroscopically normal lung tissue at transplantation, with the patient 
having no reported presence of PAH.  PAH-PASMCs were explanted from the distal 
pulmonary arteries of patients diagnosed with PAH immediately after 
pneumonectomy.  The hPASMCs were isolated from peripheral segments of artery 
(0.3 to 1.0mm external diameter) by microdissection, as previously described (6). For 
experiments PASMCs were plated in 10% FBS/DMEM and used between passages 
5 to 8. Cultured hPASMCs were confirmed by both staining for ±-smooth muscle 
actin (>97% ±-smooth muscle actin–positive cells) and morphological 
characterization (6).  Table E3 describes the clinical characteristics of the human 
cells and tissues studied. 
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Figure E1 
Systemic arterial blood pressure and heart rate in chronic hypoxic mice model 
treated with anastrozole.  Effects of the aromatase inhibitor, anastrozole (ANA) 0.3 
mg
-1
kg
-1
day
-1
 and 3 mgkg
-1
day
-1
 for 14 days on (A) systemic arterial pressure(mSAP) 
(n=7-9 per group) and (B)  heart rate (HR) in female mice  (n=7-9 per group); and 
effects of anastrozole 3 mgkg
-1
day
-1
  for 14 days on (D) mSAP (n=6 per group) and 
(E) HR in male mice  (n=6 per group). Data displayed as mean ± SEM, analysed by 
one-way ANOVA with Bonferroni post test. 
 
Figure E2 
Estrogen receptor expression is altered in female mouse pulmonary artery in 
hypoxia.  Female mice:  (A) ER± protein expression and (B)  ER²  protein 
expression in normoxic and hypoxic pulmonary arteries from female mice.  Male 
mice:  (A) ER± protein expression and (B) ER²  protein expression in normoxic and 
hypoxic pulmonary arteries from male mice.  Representative immunoblots and graph 
showing quantification comparing ER± and ER²  expression for n=3 pulmonary 
arteries per group.  Data are shown as mean ± SEM and analysed using an unpaired 
t-test.  *p<0.05 vs. Normoxic 
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Figure E3 
MPP 2mgkg-1day-1 attenuates the development of hypoxic pulmonary hypertension 
in female mice whilst male mice are unaffected.  A-D: female mice.  Right 
ventricular systolic pressure (RVSP) (A), right ventricular hypertrophy (RV/LV+S) (B) 
and pulmonary vascular remodelling (C&D) assessment in female mice.  E-H: male 
mice.  RVSP (E), RV/LV+S (F) and pulmonary vascular remodelling (G&H) are 
unaffected in males.  Representative images of distal pulmonary arteries from each 
group are shown, (alpha-SMA stains dark brown).  Data are expressed as ± SEM 
analysed by two-way ANOVA followed by a Bonferroni post-hoc test.  * p<0.05; ** 
p<0.01; *** p<0.001 vs. normoxic; † p<0.05 vs. vehicle.  n=6-9 per group.  Scale bar 
(-)=20µm. 
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Figure E4 
Effect of aromatase inhibition on cardiac function the female and male 
Su5416/hypoxia(Su/Hx) rats.  (A)  Cardiac output as determined by echocardiogram 
on day 14 (D14) and day 28 (D28) following administration of Su/Hx in female rats 
treated with or without anastrozole (ANA) 0.03 mgkg-1day-1, 0.3 mgkg-1day-1 or 3 
mgkg-1day-1 in female rats (n=4-5 per group) and (B) Pulmonary artery acceleration 
time measured serially by echocardiogram at days 0, 14 and 28 in female Su/Hx rats 
treated with or without anastrozole  (n=5 per group).  Cardiac parameters were also 
studied in male Su/Hx rats.  (C)  Cardiac output as determined by echocardiogram 
on day 14 (D14) and day 28 (D28) following administration of Su/Hx in male rats 
treated with or without anastrozole 3 mgkg-1day-1 (n=5 per group) and (D) Pulmonary 
artery acceleration time at days 0, 14 and 28 in male SUGEN/hypoxic rats treated 
with or without anastrozole (n=5 per group).  Data displayed as mean ± SEM. 
**p<0.01 as indicated, determined by one-way ANOVA with Dunnett’s post test. 
 
Figure E5 
Examples of aromatase immunoreactivity in human lung and human microvascular 
pulmonary artery endothelial cells (hMPAECs).   (A) Representative image of IgG 
controls in mouse, rat and human pulmonary artery.  (B) Representative images 
showing aromatase immunolocalisation in a pulmonary artery from a female PAH 
patient (aromatase = pink; ±-smooth muscle actin (±-SMA) = brown; von Willebrand 
factor (vWF) = brown; scale bar (-) indicates 500µm).  b corresponds to patient 
information in Supplemental Table E3. (C)  Immunoblot showing absence of 
aromatase expression in hMPAECs from 4 separate samples.  Mouse uterus was 
used as a positive control for the aromatase antibody. 
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Figure E6 
Effects of aromatase inhibition on hypoxia and Su/Hx-induced changes in Id 
expression. A-B:  hypoxic mice.  Relative gene expression levels in whole lung of 
(A) Id1 and (B) Id3 in male and female normoxic and hypoxic mice treated with or 
without anastrozole (ANA) 3 mgkg-1day-1 (n=6 per group).  D-F: Su/Hx rats. (C) Id 1 
and (D) Id3 relative mRNA levels in female and male normoxic and SUGEN/hypoxic 
rat lung treated with or without anastrozole 3 mgkg-1day-1 for 14 days (n=5-6 per 
group). Gene expression levels are normalised to ² -2-microglobulin (² 2M). Data 
displayed as mean ± SEM. *p<0.05 and **p<0.01 as indicated, determined by one-
way ANOVA with Bonferroni post test.   
 
Figure E7 
Effects of ER± antagonist MPP on BMPR2 and Id1 expression in hypoxic female 
mice.  Relative gene expression levels of A BMPR2 and B Id1 in whole lung form 
female normoxic and hypoxic mice treated with or without MPP 2mgkg-1day-1 (n=6 
per group).  Gene expression levels are normalised to GAPDH). Data displayed as 
mean ± SEM. *p<0.05 and **p<0.01 as indicated, determined by one-way ANOVA 
with Bonferroni post test.   
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Figure E2 
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Figure E3 
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Figure E7  
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Gene Species Assay ID 
 
BMPR2 Mouse 
Rat 
Mm00432134_m1 
Rn01437213_m1 
Id1 Mouse 
Rat 
Mm00775963_g1 
Rn00562985_s1 
Id3 Mouse 
Rat 
Mm01188138_g1 
Rn04219390_g1 
² -2-microglobulin Mouse 
Rat 
Mm00437762_m1 
Rn00560865_m1 
 
Table E1.  TaqMan gene expression assays purchased from Applied Biosystems. 
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Antibody Type (Clone) Source  
(catalogue number) 
Dilution used 
 
 
Aromatase Rabbit polyclonal Abcam (ab69653) Immunoblotting: 1:1000 
Immunohistochemistry: 1:120 
 
BMPR2 Mouse monoclonal BD Bioscience (612292) Immunoblotting: 1:500 
 
GAPDH Mouse monoclonal 
[mAbcam 9484]  
Abcam (ab9482) Immunoblotting: 1:10000 
 
 
±-SMA Rabbit polyclonal Abcam (ab5694) Immunohistochemistry: 1:500 
 
vWF Rabbit polyclonal Dako (A0082) Immunohistochemistry: 1:1000 
 
 
Table E2.  Specifications and sources of antibodies used for immunoblotting and 
immunohistochemistry.   
±-SMA indicates ±-smooth muscle actin and vWF indicated von Williebrands factor. 
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 Tissue Type Available Patient information BMPR2  
mutation  
Non PAH - 
Female 
PASMCs   1. 58 year old 
2. 64 year old  
3. 59 year old 
4.  64 year old 
 
    
PAH - 
Female 
Lung a. 26 year old, HPAH, transplant, meanPAP 
58mmHg 
b. 30 year old HPAH, transplant, meanPAP 
46mmHg 
c. 38 year old HPAH, transplant, meanPAP 
56mmHg 
d. 19 year old HPAH, transplant 
e. 26 year old IPAH, transplant 
f. 44 year old IPAH, transplant 
g. 51 year old IPAH, transplant 
h. 23 year old IPAH, transplant 
 
 
Yes 
Yes 
 
 
 
 
 
 PASMCs       5.   24 year old , IPAH 
      6.   39 year old, HPAH 
      7.   30 year old, HPAH 
 
 
 
Yes  
Yes 
Non PAH - 
Male 
PASMCs       8.  72 year old 
      9.  76 year old 
    10.  62 year old  
    11.  54 year old 
 
    
PAH - Male Lung i. 23 year old, HPAH, transplant, meanPAP 
54mmHg 
j. 43 year old, IPAH, transplant, meanPAP 
62mmHg 
k. 56 year old, IPAH, transplant 
Yes 
 
Table E3.  Clinical characteristics of the human cells and tissues studied.  PASMCs 
= pulmonary artery smooth muscle cells, IPAH = idiopathic pulmonary hypertension, 
HPAH = heritable PAH and PAP = pulmonary artery pressure. 
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